Why Amarin's Shares Dropped

• Report this Comment On July 27, 2012, at 3:55 PM, Capeital wrote:

  What were the restrictions? They got an excellent label. Next is NCE. Buyout/partnership has strong possibilities.

  Did you listen to the conference call?

  I don;t get where you guys come up with negative stuff all the time.

  State facts and not generic 3rd grade writing.

• Report this Comment On July 27, 2012, at 4:11 PM, riggsfamily5 wrote:

  I think people are over playing the indication language because there doctors typically Rx on indications and off indications on drugs like Amarin's - especially considering how safe and efficacious the Anchor trial proved to be.

• Report this Comment On July 27, 2012, at 4:12 PM, 2005jaydog wrote:

  A spreadsheet??? Let's talk sNDA for high trigs; 889 patent coming soon and NCE. This was one big tree-shaking action of a day - with weak handed shares falling out all over the place. Oh yeah.... how about a buyout probability as well as the REDUCE IT study getting to the 'well underway' point. I'm not discouraged - just do some homework before you write inaccurate. misleading crap. Spreadsheet????

• Report this Comment On July 27, 2012, at 4:17 PM, venus537 wrote:

  It was NO surprise that this approval would be for only the Marine data. But Amarin got Got all 5 indications they wanted in label, including ApoB.

  A second sDNA will come later this year for the Anchor data which has a wider market.

  It was also no surprise that NCE status wouldn't be known until this August.

  You may be right about why investors were disappointed but if that's the case they are clueless about what was expected with approval. In reality it went great.

• Report this Comment On July 27, 2012, at 4:20 PM, BiotechWill wrote:

  This is perhaps one of the worst articles I have read on this site, if for no other reason than its misleading nature.

  When the drug was approved yesterday, Vascepa got a very favorable label. The Anchor trial results, which I am assuming are what you are referencing when you reference "investors being disappointed" were not expected to be included on this label at all - the timing of that SNDA filing was slotted for later in 2012.

  As for a market limitation, the available market with just the current indication is huge, actually surpassing Lovaza because Vascepa does not raise LDL.

  Although I normally try to keep my comments positive and encouraging, it is clear that you did not perform your due diligence here - otherwise you would understand that investors that understand the drug were actually very excited yesterday, and will patiently await a slew of catalysts that will do nothing but increase PPS.

• Report this Comment On July 27, 2012, at 4:22 PM, Capeital wrote:

  I guess MF shorted the stock. You guys don't have a clue as to what happened, or will happen. Do some dd and I strongly suggest you listen to the conference call and read the PR.

  Just the truly uninformed listen to anything MF says about any company.

  You sure got this one wrong.

  Again state the restrictions and facts. Can you?

  There are none.

• Report this Comment On July 27, 2012, at 4:27 PM, Mwachovia wrote:

  I agree 110%

  You guys are a bunch of crooks. Just yesterday you were publishing articles saying Buy, buy, buy! And less than 24hrs. It's sell, sell, sell. Some of you authors are almost as crooked as the banks.... Do your job right! Blasphemy...

  See you at the buyout suckers.....

  Long amrn

• Report this Comment On July 27, 2012, at 4:32 PM, Capeital wrote:

  Here's the link for the webcast that you obviously didn't listen to. You can also read the PR here.

  Man you guys could pizz off the pope with your nonsense.

  http://investor.amarincorp.com/events.cfm

• Report this Comment On July 27, 2012, at 4:37 PM, venus537 wrote:

  Great write up BiotechWill, you stated what I wanted but much better.

  Unfortunately, this article is not alone with its sentiment. What I don't understand is if any journalist is going to do a write up about Amarin today why wouldn't they listen to yesterday's conference call if for nothing else to get another perspective.

• Report this Comment On July 27, 2012, at 4:52 PM, skm1965 wrote:

  Your article did not present any information that helps investors.However comments by readers are great.

  Bad teacher-but Great Students-- Successful school with great results.

  1) FDA labelling was based on Marine data-for high Triglceride patients.Anchor trial data will be filed during next few months-for population with TRIG.--250-500mg.

  2) NCE decision is made in Aug.2012--for those who got FDA approval in July.

  3)Sales estimates are 1-2 billion$--could go higher with use with 250-500mg.Population and worldwide marketing in Europe ,Brazil,Russia. Japan has Epadel already with 500 mil.$ sales-Epadel is also pure EPA.

  4) Canccord Genuity and Leerink Swan raised target from 25 to 27$/share on 7/27/2012.

  5) My guess--merger/acquistion by Astra Zeneca at 27-30$/share by Dec.2012.

  Astra Zeneca has sales force/marketing prowness to increase its potential.

  I think--rumors will be flying within next 30 days after NCE decision and more patents news.

• Report this Comment On July 27, 2012, at 4:57 PM, skm1965 wrote:

  Good that stock is down--offers good opportunity to double in 5 months-with a White Knight-Astra Zeneca.

• Report this Comment On July 27, 2012, at 4:58 PM, mincasa wrote:

  Befor the open today the stock went as high as $15.80!! so your theo "The restrictions will limit the overall addressable market for the drug out of the gate, which is an outcome that would understandably damper investor enthusiasmry of

  Is nothing but false...What happened today just re inforced the fact that AMRN will be bought out for a huge sum pps, in the very ,very , very near future. WS took out their arsenal of WMD and went crazy today, shaking shares from week hands..I wouldnt be surprised if AMRN's exec. are all in on all of this , buying shares under other peoples names away from SEC eyes, so that they can cash in when the buy out is done...There was no medical related or scintific related reason as to the quality of this drug , for its shares to be slammed lto this degree...but there is one thing for sure, there is a GOD watching everyone, and who knows , may be the one;s that slaughtred this stock will be in need for this and all other drugs they kill evey day, see you all at the buy out..long AMRN.

  p.s. Why then all these upgrades with pps targets at $25-$30 from all these so called respected ANALyists??

• Report this Comment On July 27, 2012, at 5:03 PM, sbeefyk1 wrote:

  There's a lot of frustrating hate in these comments. I'll admit I am currently holding a long position in AMRN. Yes, that's right, I did not sell today because I believe the stock is worth much more. But it seems there's been some confusion.

  Even though AMRN only applied for marketing approval for very high TG, many people, including AMRN, were hopeful that the FDA would allow prescription for high TG as well. I did not expect this to happen, but it wasnt 100% out of the question. I was there for the CC and yes AMRN was very please with the label, as was I. But the truth is many people were hopeful for high TG. It will come later though. Perhaps mid-2013?

  Another issue that caused the share price to drop is a lack of knowlede regarding the Orange Book. For some reason many investors (or biotech traders) thought the FDA was going to grant NCE at the same time as the approval. When in reality they are completely different processes. Not to mention many people became delirious that AMRN will announce a buyout yesterday. So when none of this came the stock plummeted.

  Point is the stock dropped and the author explained a possible reason. For those asking for the proof of label restrictions, then well the explanation is the FDA not giving Vascepa the high TG market. Only very high TG. It's not really a restriction considering AMRN only applied for very high TG. But again, some people do not know that.

  My PT was and still is 16. Until we get some proof of a marketing deal then I will not move it higher.

• Report this Comment On July 27, 2012, at 5:30 PM, BiotechWill wrote:

  I just wanted to add one thing to this discussion - if you look on the FDA website, you'll note that Vascepa is listed as a drug with "No therapeutic equivalent."

  Part of the process of getting that listing is not being pharmacologically equivalent, which in my mind translates to "different active moiety", which translates to NCE.

• Report this Comment On July 27, 2012, at 5:52 PM, venus537 wrote:

  sbeefyk1,

  There is a big difference between hope and expectations.

  Agreed, there was a "slim" possibility the FDA would allow a label for high GT, but Amarin was "ecstatic" with the label they got as you said. And it's my understanding doctors are free to prescribe off label anyway.

  I'm not sure how a knowledgeable investor would dump the stock on these grounds as overall Amarin still received a great indication.

  Like you implied, the sell off may have been the result of a lack of knowledge.

  Keep in mind we will soon get notices of allowance for key patents and likely NCE status in August so we'll see if $16 is the ceiling.

  I like to think the conventional wisdom will catch up to reality to further spark the stock. This stock is in a much stronger position now then when it was last year when it got to $19+. And lets don't discount rumors of a buyout, sometimes a lack of real knowledge can be a benefit.

• Report this Comment On July 27, 2012, at 8:48 PM, Capeital wrote:

  You may want to read this from a Phd MF contributor.

  It appears he gets it.

  http://www.dailyfinance.com/2012/07/27/approved-drug-for-sal...

• Report this Comment On July 27, 2012, at 9:19 PM, trufflestuff wrote:

  I believe that the main reason investors dumped their share myself included is that there were no price changes after the trading halt! I was expecting higher opening price to boost investor's confidence just like ARNA & VVUS, both HZNP and AMRN traded lower just after the approval. It's really sad because I waited for the PDUFA result though I want to sell my share to buy Sprint instead, the market rallied but AMRN went opposite.

• Report this Comment On July 27, 2012, at 11:15 PM, asp924 wrote:

  Your MF article is full of misleading information. You basically are saying that AMR101's labelling was worse than expected and it now places strict restricttions on the drug and who can get prescriptions from it.

  All of that is wrong. Please next time before you write an article, present it in a factual way instead of negative misleading info where the average joe will intepret it as SELL MORTIMOR!! SELL

Add your comment.